Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Janssen Pharmaceuticals, Inc.
Sort By
Newest First
1 / 2
1 / 2
Agreement
Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38
Genmab
PR-M06-19-NI-007
Jun 12, 2019
Drug Development
Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cance
Janssen Pharmaceutical Companies
PR-M05-19-NI-001
May 01, 2019
FDA Approval
U.S. FDA Approves DARZALEX® (daratumumab) Split-Dosing Regimen
Janssen Pharmaceutical Companies
PR-M02-19-NI-028
Feb 13, 2019
Phase 3
New DARZALEX® (daratumumab) Phase 3 Study Shows Efficacy and Safety Data of Anti-CD38 Monoclonal Antibody in Patients with Newly Diagnosed Multiple Myeloma
Janssen Pharmaceutical Companies
PR-M12-18-NI-019
Dec 06, 2018
Depression
New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans
Janssen Pharmaceutical Companies
PR-M10-18-NI-104
Oct 30, 2018
Clinical Data
Janssen Announces New Three-Year TREMFYA® (Guselkumab) Data Demonstrates Stably Maintained Rates of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis
Janssen Pharmaceutical Companies
PR-M10-18-NI-073
Oct 22, 2018
RNA
Janssen Collaborates on RNA Therapy
Nice Insight
PAO-M10-18-NI-008
Oct 11, 2018
New Drug Application
Janssen Submits New Drug Application to U.S. FDA Seeking Approval of Erdafitinib for the Treatment of Metastatic Urothelial Cancer
Janssen Pharmaceutical Companies
PR-M09-18-NI-083
Sep 26, 2018
Study Results
Janssen Reports Positive Topline Results for ATLAS Phase III Study of a Novel, Long Acting Injectable Two-Drug Regimen for the Treatment of HIV-1
Janssen Pharmaceutical Companies
PR-M09-18-NI-045
Sep 17, 2018
Regulatory
Janssen Submits U.S. & EU Regulatory Applications Seeking Approval of DARZALEX® (daratumumab) Split Dosing Regimen
Janssen Pharmaceutical Companies
PR-M08-18-NI-093
Aug 23, 2018
Positive Opinion
Janssen Receives Positive CHMP Opinion for Darzalex®▼ (daratumumab) as Frontline Treatment for Newly Diagnosed Patients with Multiple Myeloma
Janssen Pharmaceutical Companies
PR-M08-18-NI-007
Aug 02, 2018
FDA Approval
Janssen Announces U.S. FDA Approval of SYMTUZA™ (D/C/F/TAF), the First and Only Complete Darunavir-Based Single-Tablet Regimen for the Treatment of HIV-1 Infection
Janssen Pharmaceutical Companies
PR-M07-18-NI-061
Jul 19, 2018
Janssen Announces Initiation of Phase 1b/2 Clinical Development Program Evaluating JNJ-68284528 CAR-T Cells for the Treatment of Multiple Myeloma
Janssen Pharmaceutical Companies
PR-M06-18-NI-005
Jun 01, 2018
Real-World Study
New Real-World Study Finds Long-Term XARELTO® (rivaroxaban) Use Resulted in Fewer Strokes and Systemic Emboli
Janssen Pharmaceutical Companies
PR-M05-18-NI-101
May 28, 2018
Commission Approval
Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
Janssen Pharmaceutical Companies
PR-M05-18-NI-088
May 23, 2018
Data Presentation
Janssen to Present Data in Treatment-Resistant Mental Ilnesses
Janssen Pharmaceutical Companies
PR-M05-18-NI-029
May 08, 2018
Acquisition
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens
Janssen Pharmaceutical Companies
PR-M05-18-NI-021
May 07, 2018
Study
Real-World Study Shows INVOKANA® (canagliflozin) 300mg Demonstrates Better Blood Glucose Control Than Farxiga® (dapagliflozin) 10mg in Patients with Type 2 Diabetes
Janssen Pharmaceutical Companies
PR-M05-18-NI-010
May 02, 2018
Cardiovascular
Janssen Announces Worldwide Development and Commercialization Collaboration with Bristol-Myers Squibb to Advance a Next-Generation Therapy for Cardiovascular Diseases
Janssen Pharmaceutical Companies
PR-M04-18-NI-72
Apr 20, 2018
Biologics
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the Bar in Psoriasis Management
Spherix Global Insights
PR-M03-18-NI-040
Mar 12, 2018